Valuation: Genelux Corporation

Market Cap 118M 102M 95.47M 87.11M 164M 11.22B 167M 1.12B 439M 5.62B 442M 432M 18.74B P/E 2026 *
-3.23x
P/E 2027 * -3.54x
Enterprise Value 118M 102M 95.47M 87.11M 164M 11.22B 167M 1.12B 439M 5.62B 442M 432M 18.74B EV / Sales 2026 *
-
EV / Sales 2027 * 9.66x
Free-Float
86.06%
Yield 2026 *
-
Yield 2027 * -
1 day-2.57%
1 week-6.03%
Current month-9.86%
1 month-12.54%
3 months-8.62%
6 months+9.50%
Current year-39.22%
1 week 2.5
Extreme 2.5
2.78
1 month 2.5
Extreme 2.5
3.08
Current year 2.29
Extreme 2.29
4.99
1 year 2.29
Extreme 2.29
8.54
3 years 1.6
Extreme 1.6
30.44
5 years 1.6
Extreme 1.6
40.98
10 years 1.6
Extreme 1.6
40.98
Manager TitleAgeSince
Chief Executive Officer 67 2014-05-27
Director of Finance/CFO 42 2025-01-29
Chief Tech/Sci/R&D Officer 55 2026-04-30
Director TitleAgeSince
Director/Board Member 68 2002-08-31
Chairman 73 2013-12-31
Chairman 67 2023-03-31
Date Insider Type Main position Quantity % Market Cap.
8/4/26 Sell

Chief Technology Officer

-653 0.0015%
8/4/26 Sell

Chief Technology Officer

-653 0.0015%
8/4/26 Sell

Chief Executive Officer

-3,023 0.0067%
Change 5-day change 1-year change 3-year change Capi.($)
-2.57%-6.03%-19.21%-88.56% 121M
-0.70%+13.34%+75.61%+103.83% 70.85B
-2.35%+2.88%+35.39%+64.72% 55.41B
-1.62%+34.25%+17.43%+491.04% 29.43B
-0.30%+13.64%+54.71%+6.07% 24.12B
0.00%+1.59%-15.06%-13.21% 23.31B
+0.05%+6.12%+46.81%-21.81% 18.37B
+9.77%+20.16%+260.17%+472.38% 16.99B
0.00%+9.69%+31.01%+584.59% 16.1B
-3.08%-8.34%+37.21%+138.52% 13.12B
Average -0.08%+160.71%+52.41%+173.76% 26.78B
Weighted average by Cap. -0.41%+218.74%+56.25%+164.57%

Financials

2026 *2027 *
Net sales - 12.18M 10.56M 9.88M 9.02M 16.97M 1.16B 17.25M 116M 45.4M 582M 45.74M 44.74M 1.94B
Net income -37.1M -32.15M -30.1M -27.46M -51.68M -3.54B -52.55M -353M -138M -1.77B -139M -136M -5.91B -37.87M -32.82M -30.72M -28.03M -52.75M -3.61B -53.63M -360M -141M -1.81B -142M -139M -6.03B
Net Debt - -
Logo Genelux Corporation
Genelux Corporation is a late clinical-stage biopharmaceutical company. The Company is focused on developing a pipeline of next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its clinical and preclinical product candidates are intended to selectively kill tumor cells and induce a robust immune response against a patient’s tumor neoantigens. Its product candidate, Olvi-Vec (olvimulogene nanivacirepvec), is a proprietary, modified strain of the vaccinia virus (VACV), a stable deoxyribonucleic acid (DNA) virus with a large engineering capacity. Olvi-Vec is developed for the treatment of multiple cancers based on the results of preclinical studies that suggest Olvi-Vec has the potential to infect and directly kill a wide range of tumor cell types in vitro and in vivo and produce an anti-tumor immune response. Its portfolio also include oncolytic vaccinia immunotherapy clinical candidates.
Employees
26
Date Price Change Volume
26-08-11 US$2.650 -2.57% 315,950
26-08-10 US$2.720 +2.26% 434,431
26-08-07 US$2.660 -1.48% 246,863
26-08-06 US$2.700 +7.57% 209,650
26-08-05 US$2.510 -10.99% 950,188
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
2.650USD
Average target price
17.50USD
Spread / Average Target
+560.38%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. GNLX Stock